Consolidated operating income grew by 31.7% year-on-year to INR50.1bn ($605.8m) on the back of strong growth in the US business
US contributed 46% to net Q4 sales of INR48.5bn. Sales from the geography were up 58% year-on-year at $275mn
US reported strongest-ever quarterly sales and one of the highest quarterly EBITDA margin of 26.2% in the past five years
Launch of generic (g)Trokendi (topiramate) used to treat seizures and prevent migraine and the continuing gains from a generic to Bristol Myers Squibb Company’s Revlimid (lenalidomide) aided margins.
Nuvama estimated $65-75m contribution from gTrokendi and gRevlimid (Also see "Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out" - Scrip, 1 December, 2022.)
The India formulations business contributed 26% to net sales and grew 11% year-on-year
The consumer wellness business added 15% to net sales and grew 12% year-on-year

Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US

gRevlimid, gTrokendi Drive Record US Sales